Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like; y is 0 or 1; R1 is hydrogen or the like; R2a and R2b are taken together with an adjacent carbon atom to form ring B; ring B is a substituted or unsubstituted non-aromatic carbocycle or the like; R3a is hydrogen or the like; R3b is hydrogen or the like; R4a is represented by formula: L1 is a single bond or the like; L2 is —C(?O)— or the like; La is a single bond or the like; R7 is substituted or unsubstituted alkyl or the like; R4b is substituted or unsubstituted alkyl or the like; R4c is each independently halogen or the like.

Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: is or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

Abstract: The present invention provides a compound represented by formula (I): wherein the dashed line indicates the presence or absence of a bond; R1 is carboxy or the like; L is substituted or unsubstituted non-aromatic carbocyclyldiyl or the like; R2 is substituted or unsubstituted alkyl; R3 is a hydrogen atom or the like; X is ?CRX— or ?N—; Y is ?CRY— or ?N—; U is —CRU? or —N?; V is —CRV? or —N?; W is ?CRW— or ?N—; ZA is —C? or —N—; ZB is —CR5R6— or the like; ZC is —CR7R8— or the like; RX, RY, RV and RW are each independently a hydrogen atom or the like; RU is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; R7 and R8 are each independently a hydrogen atom or the like; R4 is substituted or unsubstituted alkyloxy or the like, or a pharmaceutically acceptable salt thereof, having an antiviral activity; and a pharmaceutical composition comprising the same.

Abstract: The present invention provides a compound represented by a following formula. A compound represented by, wherein R1 is hydrogen, hydroxy, or the like; R2a and R2b may be taken together with an adjacent carbon atom to form ring B, ring B is a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle; R3a is hydrogen, halogen, hydroxy, or the like; R3b is hydrogen, halogen, hydroxy, or the like; R4a is a group represented by formula: L3 is a single bond or substituted or unsubstituted alkylene, R7 is hydrogen, halogen, hydroxy, or the like, and R4b is halogen, cyano, carboxy, or the like, or its pharmaceutically acceptable salt.

Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.

Abstract: The present invention provides a compound of formula (1), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.

Abstract: A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R1, R2, R3, R4a, R4c, R5 are as defined in the description.

Abstract: A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R1, R2, R3, R4a, R4c, R5 are as defined in the description.

Abstract: The present invention provides a compound of formula (1), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.

Abstract: A compound of formula (I) wherein variables are as defined herein having an autotaxin inhibitory effect and a pharmaceutical composition comprising the same.